| INTRODUCTION
The gastrointestinal (GI) microbiome comprises trillions of microbial organisms and has emerged as an important regulator of metabolic health.
In-depth examination of the GI microbiome has shown clear changes in the microbial community during obesity, 1 and importantly, that these changes can drive metabolic changes. 2 Recently, the methanogenic archaea (methanogens) have been identified as a potential regulator of metabolic function. These microorganisms metabolize a variety of electron sources including dihydrogen gas and small fatty acids within the gut milieu to produce methane (reviewed in 3 ). While not all humans have detectable levels of breath methane, studies have shown that methane production is altered in disease states. Indeed, It appears that faecal methanogen numbers are elevated during human obesity and that disrupting methanogens through antibiotic treatment of their bacterial syntrophs also corresponds to reduced insulin secretion. 4 These studies suggest that methanogens and methane might have a role to play in the regulation of glucose homeostasis during obesity, though whether linkages are direct or spurious is unclear, and our understanding of how methane might drive metabolic changes is unknown.
One potential mechanism explaining methane's action on metabolic health may be through direct action on the GI endocrine system.
Indeed, in addition to housing methanogens, the GI tract is also home to a variety of metabolic hormone-secreting cells, known collectively as the enteroendocrine system. Specifically, glucagon-like peptide-1 
| Methanogen detection
DNA from caecal and faecal samples (25 mg) were isolated using the PowerFecal ® Isolation Kit (MoBio, Carlsbad, CA, USA). Quantitative PCR was performed targeting the mcrA gene encoding a subunit of the methyl coenzyme-M reductase, a key enzyme in methanogenesis, using the primer pair described in. 9 A standard curve of template methanogen DNA with known copy number was used for downstream absolute quantification.
| Cell culture
Mouse (GLUTag) and human (NCIH716) GLP-1 secreting cells were grown under standard conditions (5% CO2, 37C). For cAMP and GLP-1 secretion experiments, cells (5 00 000) were seeded into 6 well plates for 48 hours. Methane treatments were prepared in 0.5% serum as previously described in. 10 Methane concentrations were verified in gas-phase following a liquid-headspace equilibration using a gas chromatograph with a flame ionization detector. GLP-1 secretion was examined in cell culture media after 2 hours using a commercial total GLP-1 ELISA (Sigma Aldrich, St. Louis, Missouri, MO, USA).
Intracellular cAMP levels were assayed after 30 minutes using a Cyclic AMP ELISA Kit (Cayman Chemical, Ann Arbor, MI, USA).
| Analysis
All data are presented as the mean ± standard error of the mean. 
| RESULTS

| Elevated methanogens and GLP-1 secretion in high-fat fed mice
Methanogen numbers in the faecal extracts were significantly higher than in the caecal extracts ( Figure 1A ), as such faecal DNA data were Figure 1E ).
| Methane directly stimulates the secretion of GLP-1
Mouse (GLUTag) and human (NCI-H716) L cells were treated with methane to determine whether methane was directly involved in GLP-1 secretion. In both GLUTag and NCI-H716 cells, methane had an overall significant effect (P < .05 1 way ANOVA, Figure 2A-B) . In GLUTag cells, strong stimulatory effects were observed at 27 μmol/L (1.95-fold of control) and 2.7 μmol/L (1.58-fold of control) (Figure 2A ).
In NCI-H716 cells, the strongest stimulation was observed at 2.7 μmol/L methane (2.19-fold of control). To determine a possible mechanism for increased GLP-1 secretion, the level of intracellular cAMP was measured and shown to increase substantially under 2.7
and 27 μmol/L methane concentrations (1.65-and 2.33-fold of control respectively, Figure 2C ).
| CONCLUSIONS
While changes in the microbiome during obesity and diabetes have been examined in several studies, the precise mechanism of how Obesity has previously been correlated with increased breath methane levels in humans 11 ; therefore, we aimed to stimulate a similar scenario in mice using a high-fat diet. Our diet intervention led to a significant increase in faecal methanogen abundance as assessed by mcrA gene copy numbers. Interestingly, these same animals had an enhanced glucose-stimulated GLP-1 secretion and a significant positive correlation between methanogen abundance and GLP-1 secretion
response. This enhanced GLP-1 secretion in obesity may seem in contrast to the known reduction in GLP-1 response found in obese and type 2 diabetic humans. 12 However, studies examining early 6-week diet-induced weight gain in rats have observed a gradual increase in the GLP-1 secretion response to nutrients. 13 Furthermore, GLP-1 levels in adolescent humans are higher in obese non diabetics vs diabetics. 14 This suggests that that an elevated GLP-1 secretion response in obesity may be protective against the development of T2DM. As diet-induced changes in the gut microbiome are also known to occur rapidly (in the span of days to weeks), 15 the timing for an interaction between methanogens or methane and GLP-1 secretion is possible.
It should be noted that our study examined faecal methanogen levels and not absolute faecal methane. Future work establishing an increase in methane gas in obesity (alongside increased GLP-1 responses) will strengthen the connection between these 2 molecules.
To demonstrate a direct link between methane and GLP-1 secretion, as opposed to indirect effects of methane precursors such as short-chain fatty acids stimulating GLP-1 secretion and methanogenesis concomitantly, 6 we tested the effect of methane alone GLP-1 has emerged as a key therapeutic in the treatment of both obesity (through appetite suppression) and T2DM (through reducing circulating glucose). As the prevalence of these diseases continues to rise, novel strategies that seek to increase the level of GLP-1 levels are needed. Together, these initial experiments demonstrate a potential beneficial role for methane in the enhancement of GLP-1 secretion.
